Natixis’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.11M | Sell |
6,599
-48,708
| -88% | -$33.2M | 0.02% | 483 |
|
|
2026
Q1 | $42.7M | Buy |
55,307
+21,507
| +64% | +$16.5M | 0.15% | 94 |
|
|
2025
Q4 | $26.1M | Sell |
33,800
-29,987
| -47% | -$20.4M | 0.09% | 168 |
|
|
2025
Q3 | $35.9M | Sell |
63,787
-8,393
| -12% | -$4.75M | 0.17% | 108 |
|
|
2025
Q2 | $37.9M | Buy |
72,180
+2,751
| +4% | +$1.54M | 0.17% | 88 |
|
|
2025
Q1 | $44.1M | Sell |
69,429
-21,615
| -24% | -$14.9M | 0.24% | 63 |
|
|
2024
Q4 | $64.9M | Buy |
91,044
+36,481
| +67% | +$30.6M | 0.4% | 41 |
|
|
2024
Q3 | $57.4M | Buy |
54,563
+30,319
| +125% | +$33.7M | 0.32% | 59 |
|
|
2024
Q2 | $25.5M | Buy |
24,244
+18,788
| +344% | +$18.2M | 0.15% | 115 |
|
|
2024
Q1 | $5.25M | Sell |
5,456
-16,576
| -75% | -$15.8M | 0.03% | 313 |
|
|
2023
Q4 | $19.4M | Buy |
22,032
+9,249
| +72% | +$7.62M | 0.14% | 143 |
|
|
2023
Q3 | $10.5M | Buy |
12,783
+153
| +1% | +$120K | 0.08% | 190 |
|
|
2023
Q2 | $9.08M | Buy |
12,630
+6,956
| +123% | +$5.36M | 0.07% | 206 |
|
|
2023
Q1 | $4.66M | Sell |
5,674
-22,732
| -80% | -$17.1M | 0.04% | 283 |
|
|
2022
Q4 | $20.5M | Sell |
28,406
-18
| -0.1% | -$13.3K | 0.12% | 164 |
|
|
2022
Q3 | $19.7M | Sell |
28,424
-21,273
| -43% | -$13.4M | 0.09% | 169 |
|
|
2022
Q2 | $29.4M | Sell |
49,697
-82,172
| -62% | -$53.4M | 0.11% | 121 |
|
|
2022
Q1 | $92.1M | Buy |
131,869
+113,811
| +630% | +$72M | 0.32% | 55 |
|
|
2021
Q4 | $11.4M | Buy |
18,058
+5,015
| +38% | +$3.08M | 0.04% | 356 |
|
|
2021
Q3 | $7.89M | Buy |
+13,043
| New | +$8.1M | 0.03% | 421 |
|
|
2021
Q2 | – | Sell |
-26,725
| Closed | -$12.6M | – | 948 |
|
|
2021
Q1 | $12.6M | Buy |
26,725
+1,368
| +5% | +$666K | 0.04% | 338 |
|
|
2020
Q4 | $12.3M | Buy |
25,357
+15,105
| +147% | +$8.15M | 0.04% | 349 |
|
|
2020
Q3 | $5.74M | Sell |
10,252
-117,743
| -92% | -$71.4M | 0.04% | 247 |
|
|
2020
Q2 | $79.8M | Buy |
127,995
+119,029
| +1,328% | +$67.6M | 0.62% | 31 |
|
|
2020
Q1 | $4.38M | Buy |
8,966
+3,240
| +57% | +$1.34M | 0.03% | 284 |
|
|
2019
Q4 | $2.14M | Buy |
+5,726
| New | +$1.93M | 0.01% | 546 |
|
|
2019
Q3 | – | Sell |
-58,307
| Closed | -$18.3M | – | 899 |
|
|
2019
Q2 | $18.3M | Sell |
58,307
-140
| -0.2% | -$46.6K | 0.14% | 140 |
|
|
2019
Q1 | $23.7M | Buy |
+58,447
| New | +$24.1M | 0.15% | 152 |
|
|
2018
Q4 | – | Sell |
-1,512
| Closed | -$611K | – | 803 |
|
|
2018
Q3 | $611K | Buy |
+1,512
| New | +$575K | ﹤0.01% | 616 |
|
|
2018
Q1 | – | Sell |
-4,893
| Closed | -$1.84M | – | 961 |
|
|
2017
Q4 | $1.84M | Sell |
4,893
-15,486
| -76% | -$6.27M | 0.01% | 424 |
|
|
2017
Q3 | $9.11M | Buy |
+20,379
| New | +$9.7M | 0.08% | 208 |
|
|
2017
Q2 | – | Sell |
-3,291
| Closed | -$1.27M | – | 959 |
|
|
2017
Q1 | $1.27M | Sell |
3,291
-5,725
| -63% | -$2.12M | 0.02% | 363 |
|
|
2016
Q4 | $3.31M | Buy |
+9,016
| New | +$3.43M | 0.03% | 299 |
|
|
2014
Q3 | – | Sell |
-7,035
| Closed | -$1.99M | – | 470 |
|
|
2014
Q2 | $1.99M | Buy |
+7,035
| New | +$2.09M | 0.02% | 235 |
|
Other funds holding REGN
Natixis's REGN Position: Q2 2026 in Review
Natixis reduced its Regeneron Pharmaceuticals (REGN) stake by 88% in Q2 2026, selling an estimated $33.2M and leaving 6,599 shares worth $4.11M. The position accounts for 0.02% of the portfolio, ranked #483.
Natixis first reported a position in REGN in Q2 2014 and has held it in 34 quarters since. The position peaked at $92.1M in Q1 2022. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Natixis held 6,599 shares of Regeneron Pharmaceuticals worth $4.11M as of Q2 2026.
- Natixis sold 48,708 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $33.2M.
- Regeneron Pharmaceuticals made up 0.02% of Natixis's portfolio in Q2 2026, its #483 holding.
- Natixis first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 34 quarters since.
- Natixis's Regeneron Pharmaceuticals position peaked at $92.1M in Q1 2022.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.